Feature image

What's New

Glucagon-like peptide-1 receptor agonists (dulaglutide, liraglutide, semaglutide, tirzepatide) and acute persistent visual loss

Medsafe has published a new monitoring communication highlighting the potential risk of acute persistent visual loss in individuals using glucagon-like peptide-1 receptor agonists, also referred to as GLP-1 receptor agonists.

We encourage healthcare professionals and consumers to report any suspected acute persistent visual loss associated with use of GLP-1 receptor agonists. Anyone can submit a report.

Go to the monitoring communication

News and Events

Date Type Title
26/1/2026Monitoring CommunicationM² Logo Glucagon-like peptide-1 receptor agonists (dulaglutide, liraglutide, semaglutide, tirzepatide) and acute persistent visual loss monitoring closes 26 July 2026
15/1/2026NoticesUpdated Clinical Trial Guidelines
15/1/2026ConsultationOutcome of the consultation on the proposed updates to the Guideline on the Regulation of Therapeutic Products in New Zealand: Clinical Trials
15/1/2026ConsultationProposed extension of the abbreviated procedure for new medicine applications and section 24(5)(a) notifications
7/1/2026NoticesNotice of Medsafe Office Closure Christmas/New Year 2025/2026
23/12/2025CommitteesMedicines Classification Committee - Dates and Deadlines
23/12/2025CommitteesMinutes of the 75th meeting of the Medicines Classification Committee - 19 November 2025
23/12/2025CommitteesMedicines Classification Committee Vacancies
15/12/2025Alert CommunicationAmended legislation about medicines that can impair driving
15/12/2025Monitoring CommunicationM² Logo Atomoxetine and the possible risk of gynaecomastia
8/12/2025ConsultationOutcome on Proposed updates to the Guideline on the Regulation of Therapeutic Products in New Zealand: Bioequivalence of medicines
8/12/2025ComplianceExemption for advertising unapproved medicines at medical conferences